Peptide bioavailability: why route matters more than dose

Key takeaways

• Bioavailability is the share of a dose that reaches the bloodstream in active form. For most peptides the route decides that share more than the dose does.
• Injection puts most of a peptide dose into circulation over hours . Semaglutide injection peaks at 1 to 3 days and has a roughly 1-week half-life from albumin binding .
• Oral peptide bioavailability is tiny. Oral semaglutide (Rybelsus) absorbs about 0.4 to 1 percent of the dose, and only because the SNAC enhancer shields it in the stomach .
• Intranasal delivery skips first-pass liver metabolism but stays low and variable for peptides. Approved nasal peptides such as desmopressin reach only a few percent of an intravenous dose .
• Buccal and sublingual absorption falls off fast with molecule size. Conventional buccal or sublingual peptide delivery reaches only about 1 to 2 percent of the dose .

Bioavailability by route, from injection to pill

What bioavailability is, and where peptides lose the dose

Bioavailability (F) is the fraction of a dose that reaches systemic circulation as the active parent molecule. Intravenous dosing is 100 percent by definition; every other route is lower. Three things set it: whether the molecule crosses the absorptive surface (skin, gut wall, nasal mucosa), whether it survives metabolism on the way (gut-wall enzymes, first-pass liver metabolism), and whether it arrives intact rather than as a breakdown product.

For peptides, the last two steps dominate. Most peptides are protease substrates with plasma half-lives measured in minutes once they reach the blood. The route therefore matters far more than it does for small-molecule drugs: each route sets both how much drug is absorbed and how fast it arrives relative to how fast the body clears it.

Subcutaneous injection: the default for therapeutic peptides

Subcutaneous (SC) injection deposits the peptide into the loose connective tissue between skin and muscle, where it is absorbed through local capillaries and lymphatic vessels. For most therapeutic peptides SC delivers a high fraction of the dose, though not always all of it: some is lost to first-pass catabolism at the injection site, and larger molecules route slowly through the lymphatics, so absorption plays out over hours rather than minutes .

GLP-1 receptor agonists show the pattern. Semaglutide injection reaches peak plasma concentration 1 to 3 days after a dose and has an elimination half-life of about 1 week, which supports once-weekly dosing. That long half-life comes from albumin binding through a fatty-acid side chain rather than from the SC depot itself . Tirzepatide follows the same shape, with a roughly 5-day half-life and once-weekly SC dosing . A peptide half-life calculator turns a published half-life into the decay and steady-state curve a given dosing interval produces.

Insulin analogs use SC routinely, and their kinetics are deliberately tuned. Insulin lispro peaks about 30 to 90 minutes after injection, while glargine and degludec reach effective levels more slowly. The difference comes from formulation excipients such as zinc and protamine and from how the molecules self-associate and then break apart in the depot .

• Absorption slows with larger molecule size, self-association into hexamers or oligomers, albumin binding, and PEGylation.
• Site rotation matters because subcutaneous tissue remodels under repeated injection (lipohypertrophy), which changes absorption; the diabetes injection literature documents this.
• Cold or warm injection sites change local blood flow and absorption rate; the effect is small for slow-release peptides and larger for fast-acting insulins.
• Inflammation at the site (recent trauma, dermatitis) can change absorption unpredictably, so the safer move is to rotate to a healthy site.

Intramuscular: faster absorption, narrower use

Intramuscular (IM) injection places the drug deeper, into a muscle belly with much higher blood flow than subcutaneous tissue. IM absorption is usually faster than SC and often produces a higher peak for the same dose. The costs are that IM injection hurts more, carries a higher needle-stick risk, and has a different infection profile because of the deeper deposit.

For most peptide therapeutics IM is not the labeled route. It shows up in emergency products, such as glucagon for severe hypoglycemia, which can be injected intramuscularly or subcutaneously , and in vaccines, where fast systemic distribution and immune-cell contact are the point. Giving a slow-release, SC-labeled peptide by IM changes the PK profile in ways the approval trials never tested, which is why off-label IM use of SC-labeled GLP-1 products is not a sound substitution.

Intranasal: works for a few peptides, poorly for most

The nasal mucosa is well supplied with blood and skips first-pass liver metabolism, so for molecules that cross it well, intranasal (IN) delivery can be fast and efficient. Peptides are mostly not those molecules. The epithelium is selective (small lipophilic molecules cross readily, large hydrophilic peptides do not), mucosal proteases degrade some peptides in transit, and the result for most therapeutic peptides is a low, variable absorbed fraction of a few percent.

• Desmopressin: intranasal desmopressin is FDA-labeled for central diabetes insipidus, but its bioavailability is only a few percent of an intravenous dose, and the nasal spray label specifically warns it is not indicated for primary nocturnal enuresis because of hyponatremia risk .
• Calcitonin (salmon calcitonin): intranasal calcitonin salmon is FDA-approved for postmenopausal osteoporosis, though the current label narrows that to women more than 5 years postmenopause when alternative treatments are not suitable and states that fracture reduction efficacy has not been demonstrated . It was for years one of the few routinely used intranasal peptides.
• Oxytocin: intranasal oxytocin is heavily studied in social-cognition and bonding research, but a critical review argues very little of an intranasal dose reaches the cerebrospinal fluid, while peripheral blood levels rise to supraphysiologic concentrations. The central-penetration premise is contested .
• Bremelanotide (PT-141): the intranasal route was studied earlier, but the approved Vyleesi product is subcutaneous, and the intranasal formulation never reached the market .

Intranasal is therefore not a generic stand-in for injection. It works for specific molecules with the right physicochemical profile and an FDA-reviewed formulation. For most injectable peptides there is no published human PK to support an intranasal version.

Oral: near-zero absorption, and the SNAC exception

An oral peptide has to clear three barriers in a row: gastric proteases, small-intestinal proteases, and the gut epithelium. Beating one helps; beating all three is rare, which is why oral peptide bioavailability for most compounds sits under 1 to 2 percent .

Oral semaglutide (Rybelsus, plus the higher-dose oral semaglutide approved for weight management in late 2025) is the established oral GLP-1 peptide. Its absolute bioavailability is only about 0.4 to 1 percent, and it works only because semaglutide is potent and because the SNAC enhancer (salcaprozate sodium) is co-formulated with the tablet: SNAC raises the local pH and increases transcellular permeability in the stomach, so a small fraction of the drug crosses the gastric wall .

A separate way around the problem is to drop the peptide entirely. In 2026 the FDA approved orforglipron (marketed as Foundayo), an oral non-peptide small-molecule GLP-1 receptor agonist; as a small molecule it is orally bioavailable without a permeation enhancer, so it sidesteps the oral-peptide problem rather than solving it .

Most peptides have neither the potency nor the formulation. Oral insulin has failed repeatedly for over half a century: the programs could not produce consistent bioavailability or reproduce the fast, reliable mealtime peak that injected insulin gives .

Buccal, sublingual, transdermal, inhaled: mostly niches

• Buccal and sublingual: these routes skip first-pass liver metabolism but need the molecule to cross the oral mucosa, and most peptides do not. Passive permeation falls off sharply with molecule size, and conventional buccal or sublingual peptide delivery reaches only about 1 to 2 percent of the dose .
• Transdermal: peptides are too large and too water-loving to cross intact skin. Iontophoresis and microneedle arrays can help but are not in routine systemic use. Topical cosmetic peptides are a separate, non-systemic use case.
• Inhaled: the alveolar surface is large and absorptive, so small peptides can reach useful pulmonary bioavailability. Inhaled insulin (Afrezza) is the surviving FDA-approved example ; an earlier product, Exubera, was withdrawn in 2007 for commercial rather than safety reasons .
• Rectal: rarely used for peptides. The lower rectum avoids first-pass liver metabolism but has low absorptive capacity for large hydrophilic molecules.

What this means when someone suggests an off-label route

When a vendor or clinician suggests taking a peptide by a route other than the labeled or studied one, the burden of proof is on them. The published PK for the labeled route does not carry over: bioavailability, time-to-peak, and degradation can shift by orders of magnitude between routes. The question to ask is whether the new route has its own published human PK, not whether the molecule has been given by some route somewhere.

For research and educational purposes only. Not medical advice.

pepSmart has not commissioned independent clinical review of this article.

More on how we write and source these pieces: Editorial process and contributor disclosure and Sourcing posture.

Spot an error? Email corrections via /about.

Sources: 15 entries, all primary canon (FDA drug labels via DailyMed, PubMed and PMC pharmacokinetics and delivery reviews, and a BMJ editorial), last reviewed 2026-07-08.

Related tools

• Tirzepatide dose calculator - Run tirzepatide-focused vial draw math.
• GLP-1 conversion calculator - Convert a GLP-1 mg dose to U-100 units and ml.
• GLP-1 ramp planner - Preview a linear educational dose-step table.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
• PK simulator overview - Public overview of the Pro pharmacokinetic simulator.
• Semaglutide dose calculator - Run semaglutide-focused vial draw math.